The Liver Study
The study drug is a potential new treatment for Non-alcoholic fatty liver disease (NAFLD).
Reimbursement: up to $10,720
Study duration: 2 screening visits, 4 MRI-PDFF total scans, 2 sets of 3-night inpatient stays, 12 follow-up visits
Inpatient Stay Dates: The start date of this study is flexible. The below dates are an example of what the schedule may look like. If you pass the initial screening, the study coordinator will arrange the exact dates with you. Please note that admission can only happen from Sunday to Thursday. Admission must be within 28 days after your initial screening. You must be available throughout April - May for your inpatient stay.
What is the purpose of this study?
Participate in a clinical study of a potential treatment for nonalcoholic fatty liver disease (NAFLD), a range of liver conditions caused by a build-up over time of fat in the liver.
NAFLD is the most common chronic liver condition in the world, can lead to cirrhosis and liver failure. Treatment options are limited and focused on lifestyle changes.
This potential treatment would work by inhibiting an enzyme that plays a role in NAFLD, with the goal of protecting the liver from damage.
Volunteers required:
- Female or Male
- BMI 27-40 kg/m2
- 18-65 years old
- No significant medical history
- Participants must have a liver fat percentage ≥6% and <33%
- Blood pressure medication may be permitted (other medications not permitted)
- Non-smokers or smoking less than 5 cigarettes per week
Call us today on 1800 243 733 to discuss your eligibility